Leap Therapeutics, Inc.

LPTX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$25,969-$16,643-$15,435-$15,431
Dep. & Amort.$775$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,156$1,489$1,204$0
Change in WC$1,749$552-$363-$2,067
Other Non-Cash$4,997$116$114$1,986
Operating Cash Flow-$16,292-$14,486-$14,480-$15,512
Investing Activities
PP&E Inv.-$1,992$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$15,984$0$0$0
Investing Cash Flow$13,992$0$0$0
Financing Activities
Debt Repay.-$13-$119-$77$0
Stock Issued$0$0$16$104
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$226$0$0$0
Financing Cash Flow$213-$119-$61$104
Forex Effect$0$22$5-$166
Net Chg. in Cash-$2,087-$14,583-$14,536-$15,574
Supplemental Information
Beg. Cash$28,849$32,713$47,249$62,823
End Cash$26,762$18,130$32,713$47,249
Free Cash Flow-$18,284-$14,486-$14,480-$15,512
Leap Therapeutics, Inc. (LPTX) Financial Statements & Key Stats | AlphaPilot